3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
beta-Thalassemia
1
Myelodysplastic Syndromes
1
Anemia
1
Interventions
pembrolizumab
37
Carboplatin
31
Cisplatin
30
Paclitaxel
23
Nivolumab
21
Pemetrexed
21
Dexamethasone
18
Gemcitabine
18
Ipilimumab
15
Docetaxel
13
Fluorouracil
13
Capecitabine
12
Rituximab
12
Cyclophosphamide
10
Cytarabine
10
Trastuzumab
9
atezolizumab
9
daratumumab
9
olaparib
9
130-nm albumin-bound paclitaxel
8
Lenalidomide
8
Prednisone
8
durvalumab
8
trastuzumab deruxtecan
8
Bevacizumab
7
Bortezomib
7
Fulvestrant
7
Oxaliplatin
7
Vinorelbine
7
cabozantinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Has announcements
×
luspatercept
×
Clear all
NCT02604433
2023-04-18
BELIEVE
Celgene
Phase 3
Completed
336 enrolled
38 charts
1 FDA
NCT02631070
2021-12-17
MEDALIST
Celgene
Phase 3
Completed
229 enrolled
36 charts
1 FDA